European regulators have awarded Amgen’s Blincyto full approval for Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow thought to affect around 900 patients a year in the region.
US regulators have approved new evidence showing that Novartis’ Cosentyx significantly slows progression of joint structural damage in patients with active psoriatic arthritis (PsA).
Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.
Roche is buying the shares it does not already own in US molecular information company Foundation Medicine (FMI), in a deal valued at $2.4 billion.
The US Food and Drug Administration has rejected Valeant group Ortho Dermatologics’ plaque psoriasis therapy Duobrii.
A £56-million drug manufacturing innovation centre – the first of its kind in the world – has been announced for Renfrewshire in Scotland.
Prime Minister Theresa May has confirmed that tax rises will be necessary to help fund the planned NHS budget increase.
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
Britain’s Dementia Discovery Fund has formed a research collaboration with US group Immuneering Corporation that aims to identify novel drug targets and candidates for Alzheimer’s disease.
Teva is discontinuing a late-stage trial assessing the efficacy of its experimental anti-CGRP therapy fremanezumab in reducing cluster headaches.
By 2023/24 there will be £20 billion more a year being spent on the NHS “in real terms”, Prime Minister Theresa May has revealed.
UK-based digital therapy group Healios has raised £2.2 million in its latest funding round.
Children and young people with X-linked hypophosphataemia (XLH) are unlikely to get routine access to Kyowa Kirin’s Crysvita on the NHS.
US regulators have again expanded the list of approved uses of MSD’s immunotherapy Keytruda, issuing a green light for the treatment of primary mediastinal large B-cell lymphoma (PMBCL).
The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.
